Correction of paralytic lagophthalmos

Anastassov, George E.; Khater, Regina H.; Anastassov, Yourii K

doi:10.2478/v10153-011-0074-x

Cited by 4 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AX 1505, an analogous orally administrable formulation, is a sustained release, floating-capsule containing cannabinoids developed by Axim Biotechnologies for the treatment of Crohn's disease. Preclinical testing of AX 1505 is in progress [79][80][81].…”

Section: Oral Administration Formulations and Modificationsmentioning

confidence: 99%

“…Clinical trials evaluating this formula-tion for pain management, multiple sclerosis-associated spasticity, Parkinson's disease, post-herpetic neuralgia, dementia, and other illnesses are ongoing. More recently, Axim Biotech has developed chewing gums with microencapsulated cannabinoids, opioid agonists, and opioid antagonists that are controlled released during mastication [79,81].…”

Section: Transmucosal Administration Formulations and Modificationsmentioning

confidence: 99%

“…THC-CBD-piperine-emulsifying nanoformulation demonstrated higher absorption rates than Sativex ® in healthy human volunteers. However, as a cytochrome and glucuronyl transferase inhibitor, piperine can modify the metabolism of several other medicines and has a nonnegligible toxicity [78,79].…”

Section: Self-emulsifying Drug Delivery Systemsmentioning

confidence: 99%

See 2 more Smart Citations

Perspectives on Challenges in Cannabis Drug Delivery Systems: Where Are We?

Palrasu¹,

Wright²,

Patel³

et al. 2022

Med Cannabis Cannabinoids

View full text Add to dashboard Cite

Cannabis and its natural derivatives have emerged as promising therapeutics for multiple pathological and nonpathological medical conditions. For example, cannabinoids, the most popular and biologically active chemicals in cannabis, aid in many clinical ailments, including pain, inflammation, epilepsy, sleep disturbances or insomnia, multiple sclerosis, anorexia, schizophrenia, neurodegenerative diseases, antinausea, and most importantly, cancer. Despite the comprehensive benefits, certain aspects of cannabis present unique challenges in the medical cannabis landscape. Recent studies have highlighted the inherent challenges associated with cannabinoids' formulation like low solubility, rapid metabolism, poor bioavailability, and erratic pharmacokinetics – all of which contribute to the limited efficacy of cannabinoids. Several efforts are underway to address the bottlenecks and modify the formulations along with the delivery systems to achieve greater solubility/bioavailability, potency, and efficacy in treatment settings while minding the necessary standards for purity associated with the pharmaceutical industry. The current article presents a perspective on (1) a working knowledge of cannabinoids and their mechanisms of action, (2) the landscape of using medicinal cannabis for cancer-related medical conditions along with adversities, (3) current approaches, formulations, and challenges in medicinal cannabis delivery systems (oral, transdermal, pulmonary, and transmucosal), and lastly, (4) emerging approaches to improve delivery systems.

show abstract

Section: Oral Administration Formulations and Modificationsmentioning

confidence: 99%

Section: Transmucosal Administration Formulations and Modificationsmentioning

confidence: 99%

See 1 more Smart Citation

Perspectives on Challenges in Cannabis Drug Delivery Systems: Where Are We?

Palrasu¹,

Wright²,

Patel³

et al. 2022

Med Cannabis Cannabinoids

View full text Add to dashboard Cite

show abstract

“…Static procedures include; lateral tarsorrhaphy, lid loading, and palpebral spring; while, dynamic include temporalis muscle transfer (TMT) and free muscle transfer. [34] The objective of dynamic procedures is to transfer a functioning motor unit to move the paralyzed eyelids.…”

mentioning

confidence: 99%

Modified silicone sling assisted temporalis muscle transfer in the management of lagophthalmos

Gupta

Kushwaha

Budhiraja

et al. 2014

Indian J Ophthalmol

View full text Add to dashboard Cite

Aim:To evaluate the efficacy of modified temporalis muscle transfer (TMT) by silicone sling for the management of paralytic lagophthalmos.Settings and Design:Prospective interventional study.Materials and Methods:Ten patients of lagophthalmos due to facial palsy underwent modified TMT using silicone sling. The patients were followed-up for a period of 3 months. Palpebral aperture in primary gaze and during eye closure were assessed both pre- and postoperatively along with problems associated with lagophthalmos like exposure keratopathy and lacrimation.Statistical Analysis:Paired t-test was applied to measure the statistical outcome.Results:Eight patients achieved full correction of lagophthalmos with no lid gap on closing the eye. The mean (standard deviation (SD)) lid gap on eye closure was 7.7 (0.86) mm preoperatively, 0.5 (0.47) mm at 1st postoperative day, and 0.7 (0.75) mm at 3rd month. There was a reduction in mean lid gap on eye closure of 7 mm at 3 months (P < 0.0001) which is highly significant. The mean (SD) vertical interpalpebral distance during primary gaze was 12.05 (1.12) mm preoperatively, 10 (0.94) mm at 1st postoperative day, and 10.35 (1.08) mm at 3rd month. There was a reduction in mean vertical inter palpebral distance of 1.7 mm at 3 months (P = 0.001) which is significant. Exposure keratitis decreased in five out of six patients at 3 months.Conclusion:Modified TMT by silicone sling is a useful procedure with lesser morbidity and good outcomes for the treatment of paralytic lagophthalmos due to long standing facial palsy.

show abstract